跳至主要内容
临床试验/2023-507842-10-00
2023-507842-10-00招募中4 期

Brain effects of hormonal contraceptives. A randomized, double-blind, longitudinal study comparing two combined oral contraceptives (Estetrol/drospirenone vs ethinylestradiol/levonorgestrel).

Region Uppsala3 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年1月18日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
60
试验地点
3
主要终点
Change from baseline to treatment in grey matter volume grey matter surface and gyrification, white matter integrity and connectivity (DTI), resting state activity and reactivity during emotion processing

研究概览

简要总结

To establish if the combined hormonal contraceptives E4/DRSP and EE/LNG have differential effects on brain structure and function.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • – be essentially healthy
  • – in need of contraception, i.e. sexually active
  • – be a woman between 18-35 years of age (i.e. ≥18 and <36 years)
  • – have a regular menstrual cycle (25-31 days) in the opinion of the investigator

排除标准

  • – History of venous thromboembolism (VTE), or first-degree relatives with a history of VTE
  • – Previous or ongoing pancreatitis
  • – Ongoing severe liver disease, or liver tumor
  • – Renal insufficiency or severe kidney disease
  • – Type 1 diabetes with vascular complications
  • – Severe dyslipidemia
  • – Migraine with aura
  • – Vaginal bleeding of unknown origin
  • – Oral cortisone treatment during the previous 3 months.
  • – Treatment with antidepressive- or antipsychotic drugs or other psychopharmaceuticals during the previous 3 months.
  • – Ongoing psychiatric disease
  • – Genetic or acquired predisposition for venous or arterial thrombosis including activated protein C resistance, anti-thrombin III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia or anti-phospholipid antibodies
  • – Premenstrual dysphoric syndrome according to daily symptom ratings on the DRSP scale
  • – Severe medical conditions in the opinion of the investigator that may interfere with compliance to treatment or study procedures
  • – Breast-feeding, pregnancy or plans of a pregnancy during the study period
  • – Concurrent participation in any other clinical trial
  • – Hearing impairments or visual impairment (> 5 degrees myopic/hyperopic or profound astigmatism)
  • – Profound fear of confined spaces
  • – Other contraindications for magnetic resonance imaging
  • – Major planned surgery, requiring immobilization.
  • – High risk for VTE due to multiple risk factors
  • – Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at screening
  • – Previous or ongoing atherosclerosis such as coronary artery disease, myocardial infarction, stroke or transient ischemic attack
  • – BMI > 30.0 kg/m2
  • – Parents diagnosed with myocardial infarction or stroke (before the age of 55 in father and before the age of 65 in mother)
  • – Previous hormone-sensitive cancer, like breast cancer, endometrial cancer or ovarian cancer

结局指标

主要结局

Change from baseline to treatment in grey matter volume grey matter surface and gyrification, white matter integrity and connectivity (DTI), resting state activity and reactivity during emotion processing

Change from baseline to treatment in grey matter volume grey matter surface and gyrification, white matter integrity and connectivity (DTI), resting state activity and reactivity during emotion processing

次要结局

  • Change in DRSP score between baseline and treatment
  • Change in Quality of Life between baseline and treatment
  • Change in depressive symptoms and anxiety symptoms from baseline

研究者

发起方
Region Uppsala
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Inger Sundström Poromaa

Scientific

Region Uppsala

研究点 (3)

Loading locations...

相似试验